ConductScience.org, home

Paper35360522

R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.

Costentin C and 26 others. JHEP Rep, 2022. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. Papers, record 35360522. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35360522

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.
PubMed
Journal
JHEP Rep
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
2.73
iCite
Revised in PubMed
2026-05-18
PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Costentin CCharlotte
2Piñero FFederico
3Degroote HHelena
4Notarpaolo AAndrea
5Boin IFIlka F
6Boudjema KKarim
7Baccaro CCinzia
8Podestá LGLuis G
9Bachellier PPhilippe
10Ettorre GMGiuseppe Maria
11Poniachik JJaime
12Muscari FFabrice
13Dibenedetto FFabrizio
14Duque SHSergio Hoyos
15Salame EEphrem
16Cillo UUmberto
17Marciano SSebastian
18Vanlemmens CClaire
19Fagiuoli SStefano
20Burra PPatrizia

Source PubMed

See all 27 authorsDownload CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03775863AFP Model and Liver Transplantation.Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References44

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110573522Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.Hepatology1999https://conductscience.org/library/papers/10573522PubMed
229376136Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort.Hepatoma Res2018https://conductscience.org/library/papers/29376136PubMed
326058462Clinicopathological indices to predict hepatocellular carcinoma molecular classification.Liver Int2016https://conductscience.org/library/papers/26058462PubMed
422282466The use and interpretation of competing risks regression models.Clin Cancer Res2012https://conductscience.org/library/papers/22282466PubMed
528199760Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models.Liver Int2017https://conductscience.org/library/papers/28199760PubMed
629433850Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018https://conductscience.org/library/papers/29433850PubMed
732201284Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.J Hepatol2020https://conductscience.org/library/papers/32201284PubMed
816794527Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma.Transplantation2006https://conductscience.org/library/papers/16794527PubMed
933479224Hepatocellular carcinoma.Nat Rev Dis Primers2021https://conductscience.org/library/papers/33479224PubMed
1024943720Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.Transpl Int2014https://conductscience.org/library/papers/24943720PubMed
1111391528Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.Hepatology2001https://conductscience.org/library/papers/11391528PubMed
1231972705Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival.Transplantation2020https://conductscience.org/library/papers/31972705PubMed
1316106022Reporting recommendations for tumor marker prognostic studies (REMARK).J Natl Cancer Inst2005https://conductscience.org/library/papers/16106022PubMed
1423278125Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.Aliment Pharmacol Ther2013https://conductscience.org/library/papers/23278125PubMed
1518581511Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies.Liver Transpl2008https://conductscience.org/library/papers/18581511PubMed
1622750200Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.Gastroenterology2012https://conductscience.org/library/papers/22750200PubMed
1722047762Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.Lancet Oncol2012https://conductscience.org/library/papers/22047762PubMed
1830229978Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation?Hepatology2019https://conductscience.org/library/papers/30229978PubMed
1926555945Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.Transplantation2016https://conductscience.org/library/papers/26555945PubMed
2018064739The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.Lancet2007https://conductscience.org/library/papers/18064739PubMed

See all 44 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
41614008Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular Carcinoma.Liver Cancer2025https://conductscience.org/library/papers/41614008PubMed
41317084Screening for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Prospective Validation of Binary Criteria.Cancer Med2025https://conductscience.org/library/papers/41317084PubMed
41249833Dual tissue mRNA and serum protein signatures improve risk stratification in hepatocellular carcinoma.NPJ Precis Oncol2025https://conductscience.org/library/papers/41249833PubMed
41024870Explant-based prognostic models for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis.World J Hepatol2025https://conductscience.org/library/papers/41024870PubMed
40656560Long-Term Prognostic Value of AFP and PIVKA-II in HCC After Living Donor Liver Transplantation: A Single-Center Retrospective Study.Transpl Int2025https://conductscience.org/library/papers/40656560PubMed
40616813Recurrence of Hepatocellular Carcinoma After Liver Transplantation: The Blind Spot of HCC Management.United European Gastroenterol J2025https://conductscience.org/library/papers/40616813PubMed
40361345Development and Validation of a Pre-Transplant Risk Score (LT-MVI Score) to Predict Microvascular Invasion in Hepatocellular Carcinoma Candidates for Liver Transplantation.Cancers (Basel)2025https://conductscience.org/library/papers/40361345PubMed
40104187Hepatocellular carcinoma recurrence after liver transplant: An Australian single-centre study.World J Transplant2025https://conductscience.org/library/papers/40104187PubMed
40070978[Hepatocellular carcinoma (HCC)].Med Trop Sante Int2024https://conductscience.org/library/papers/40070978PubMed
40067686A prospective multicenter validation of RETREAT for posttransplantation HCC recurrence prediction.Hepatology2025https://conductscience.org/library/papers/40067686PubMed
39749089Predicting Microvascular Invasion in Liver Transplant Recipients for Hepatocellular Carcinoma.Cureus2024https://conductscience.org/library/papers/39749089PubMed
39594819Response to Bridging Therapy as a Prognostic Indicator of Post-Transplantation Hepatocellular Carcinoma Recurrence and Survival: A Systematic Review.Cancers (Basel)2024https://conductscience.org/library/papers/39594819PubMed
39503026Liver transplantation for hepatocellular carcinoma: a proposal for including preoperative serological indicators improves the Milan criteria expanded.Transl Gastroenterol Hepatol2024https://conductscience.org/library/papers/39503026PubMed
39494583New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.Liver Int2025https://conductscience.org/library/papers/39494583PubMed
38927509Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence.Biomedicines2024https://conductscience.org/library/papers/38927509PubMed
38619448Alpha-fetoprotein: Past, present, and future.Hepatol Commun2024https://conductscience.org/library/papers/38619448PubMed
38473400Impact of Pre-Liver Transplant Treatments on the Imaging Accuracy of HCC Staging and Their Influence on Outcomes.Cancers (Basel)2024https://conductscience.org/library/papers/38473400PubMed
38067299Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.Cancers (Basel)2023https://conductscience.org/library/papers/38067299PubMed
36926237Current status and prospect of treatments for recurrent hepatocellular carcinoma.World J Hepatol2023https://conductscience.org/library/papers/36926237PubMed
35740638Different Models to Predict the Risk of Recurrent Hepatocellular Carcinoma in the Setting of Liver Transplantation.Cancers (Basel)2022https://conductscience.org/library/papers/35740638PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AFP174PubTator's text mininghttps://conductscience.org/library/genes/174NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35360522

GET https://conductscience.org/api/papers/v1/35360522/authors?page=2